Medicus Pharma Ltd.
No SEC Form 4 filings for $MDCX in the last 30 days.
See all $MDCX insider activity →Medicus Pharma Ltd. (MDCX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 2, 2026, Medicus Pharma Ltd. (the "Company"), through its wholly owned subsidiary, Medicus Pharma Inc., entered into a Co-Development and License Agreement (the "Agreement") with Pfizer Inc. ("Pfizer"). Under the
Thursday, the S&P 500 closed up 0.7% at a record 7,799, after briefly topping 7,800, as softer inflation data eased expectations for additional Fed rate hikes. The Nasdaq rose 0.8% to 26,803. Investors also looked ahead to earnings, including Applied Materials after the close.
Medicus Pharma (NASDAQ:MDCX) reported Q2 2026 progress in its SkinJect and Teverelix programs, including FDA “Study May Proceed” for a registrational SkinJect study in Gorlin Syndrome and UAE/IRB approvals for Teverelix Phase 2 work. Cash was $25.2M at June 30. Net loss was $11.7M ($0.21/share). The company raised about $40M in H1 2026 and warned of going-concern risk.
Over the past 7 days, alphai's AI scored 1 news story mentioning MDCX (Medicus Pharma Ltd.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent MDCX coverage spans regulation, financial news and market movers.
The partnership could significantly boost MDCX's pipeline value and future revenues, but milestones are contingent on clinical success.
Financing plus clinical/regulatory progress is a dual catalyst, improving runway while advancing programs.
Regulatory clearances for both lead programs plus a ~$40M financing and a going-concern warning create a near-term catalyst mix: upside from progress, downside from funding risk.
Regulatory progression across both SkinJect and Teverelix, alongside a strengthened cash position, should support risk-on sentiment but is tempered by going-concern language.
FDA clearance reduces regulatory uncertainty for SkinJect’s Gorlin syndrome pathway and sets up near-term catalysts around recruitment and Phase 2b progress.
alphai scores every news story that mentions MDCX with an AI model for sentiment and relevance, and aggregates insider trades from Medicus Pharma Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Medicus Pharma Ltd. (MDCX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 2, 2026, Medicus Pharma Ltd. (the "Company"), through its wholly owned subsidiary, Medicus Pharma Inc., entered into a Co-Development and License Agreement (the "Agreement") with Pfizer Inc. ("Pfizer"). Under the
1 min readThursday, the S&P 500 closed up 0.7% at a record 7,799, after briefly topping 7,800, as softer inflation data eased expectations for additional Fed rate hikes. The Nasdaq rose 0.8% to 26,803. Investors also looked ahead to earnings, including Applied Materials after the close.
6 min readMedicus Pharma (NASDAQ:MDCX) reported Q2 2026 progress in its SkinJect and Teverelix programs, including FDA “Study May Proceed” for a registrational SkinJect study in Gorlin Syndrome and UAE/IRB approvals for Teverelix Phase 2 work. Cash was $25.2M at June 30. Net loss was $11.7M ($0.21/share). The company raised about $40M in H1 2026 and warned of going-concern risk.
4 min readMedicus Pharma Ltd. (NASDAQ:MDCX) reported Q2 2026 results for the three and six months ended June 30, 2026, and provided a corporate update. The company said it received FDA “Study May Proceed” authorization for its SkinJect registrational program in Gorlin Syndrome and IRB and FDA feedback for an optimized Teverelix Phase 2 study. Cash was $25.2M at June 30, 2026, with Q2 net loss of $11.7M.
6 min readMedicus Pharma (NASDAQ:MDCX) said the FDA cleared its Phase 2b registration-enabling trial for SkinJect in Gorlin syndrome. The crossover study will enroll up to 50 patients, with recruitment expected before year-end and first enrollment possibly in early next year. SkinJect is a microneedle array for basal cell carcinoma; success could support an NDA for the Gorlin indication.
4 min readFriday’s US market ended higher, with the Nasdaq up about 1% to 25,373, the S&P 500 up 0.7% to 7,489, and the Dow up 0.5% to 52,485, led by a tech rebound. The article cites company updates including Roblox, Strategy (MSTR), Rivian, Reddit, and Coinbase after their Q2 results, plus clinical and rare-earth project news for several smaller firms.
7 min readMedicus Pharma (NASDAQ:MDCX) said the UAE Department of Health Abu Dhabi granted IND authorization for its Phase 2a PRECISION-E2 trial of Teverelix in moderate-to-severe symptomatic endometriosis. The randomized, placebo-controlled study will enroll about 84 women in the UAE with four dosing arms (60 mg SC, 90 mg SC, 90 mg IM, placebo). Primary endpoint is maintaining serum estradiol in the 20-50 pg/mL Barbieri window for at least 14 days.
4 min readMedicus Pharma Ltd. (NASDAQ:MDCX) on Friday secured regulatory clearance from the United Arab Emirates Department of Health – Abu Dhabi for its PRECISION-E2 Phase 2a clinical study. The trial evaluates Teverelix in women with moderate-to-severe symptomatic endometriosis, an estrogen-dependent disease affecting roughly 10% of reproductive-age women globally.
4 min readU.S. stocks ended mixed Monday. The Dow rose 263 points (0.5%) to 52,210, the S&P 500 edged up to 7,413, and the Nasdaq fell 44 points (0.2%) to 24,932 as semiconductor shares slid. Nvidia dropped more than 4%. Oil fell over 9% on hopes for diplomacy. ASML fell after reports of China mass-producing DUV lithography machines. Earnings included Applied Digital after the close; Boeing, Coca-Cola, PayPal and UPS before the open.
6 min readMedicus Pharma (NASDAQ:MDCX) said the FDA issued a “Study May Proceed” letter allowing it to start its NDA-enabling Phase 2b registrational SkinJect study in Gorlin syndrome. The open-label trial will enroll up to 50 patients using SkinJect 200 mcg. The FDA requested protocol changes, including biopsy confirmation and longer follow-up.
4 min read
